Regenxbio Inc. (NASDAQ:RGNX)‘s stock had its “buy” rating restated by equities researchers at Piper Jaffray Cos. in a note issued to investors on Sunday. They currently have a $25.00 target price on the stock. Piper Jaffray Cos.’s price target indicates a potential upside of 7.30% from the company’s previous close.

Several other research analysts also recently commented on the company. Zacks Investment Research downgraded Regenxbio from a “hold” rating to a “sell” rating in a research note on Friday, August 12th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Monday, August 22nd.

Shares of Regenxbio (NASDAQ:RGNX) opened at 23.30 on Friday. The company’s market cap is $616.70 million. Regenxbio has a 12 month low of $7.07 and a 12 month high of $25.00. The firm has a 50-day moving average price of $16.45 and a 200 day moving average price of $12.26.

Hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its stake in Regenxbio by 33.2% in the second quarter. Perceptive Advisors LLC now owns 1,099,213 shares of the company’s stock valued at $8,793,000 after buying an additional 273,817 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Regenxbio by 213.9% in the third quarter. JPMorgan Chase & Co. now owns 1,012,666 shares of the company’s stock valued at $14,188,000 after buying an additional 690,084 shares in the last quarter. Vivo Capital LLC purchased a new position in Regenxbio during the first quarter valued at $10,697,000. Franklin Resources Inc. boosted its position in Regenxbio by 1,004.9% in the second quarter. Franklin Resources Inc. now owns 700,500 shares of the company’s stock valued at $5,604,000 after buying an additional 637,100 shares in the last quarter. Finally, BlackRock Advisors LLC boosted its position in Regenxbio by 0.9% in the third quarter. BlackRock Advisors LLC now owns 693,908 shares of the company’s stock valued at $9,722,000 after buying an additional 6,251 shares in the last quarter. Hedge funds and other institutional investors own 68.74% of the company’s stock.

Regenxbio Company Profile

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

5 Day Chart for NASDAQ:RGNX

Receive News & Stock Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related stocks with our FREE daily email newsletter.